Progenics Pharma (PGNX) Reports Q4 Loss of $0.04/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2017 Financial Results and Business Update
March 8, 2018 7:45 AM ESTCompany Preparing for Potential Commercial Launch of AZEDRA® (iobenguane I 131) Ahead of U.S. Food and Drug Administration (FDA) April 30th Action DateEnrollment Complete in Phase 3 Trial for PSMA-Targeted SPECT/CT Imaging Agent 1404; Top-Line Results Anticipated in Q318Enrollment Ongoing in Phase 2/3 Trial for PSMA-Targeted PET/CT Imaging Agent PyL and Phase 1 Trial for PSMA-Targeted Small Molecule 1095RELISTOR® Quarterly Net Sales Reached Record Level of $24.6 Million in Q417
NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:... More
